A Phase 2 interventional study of Intranasal Dexmedetomidine and Intranasal Placebo in Pain, Post-operative, sponsored by Baudax Bio. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-05-02.
Sponsored by Baudax Bio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 16th largest by enrollment, is one of 7 that started in 2014, is one of 10 in phase 2, and was the 9th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–70
Vasiliki Samartzi · Sites in Greece
Ages 20–70 · Women only
Tanta University · Sites in Egypt
Ages 21–60
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Rhode Island Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 23 · Phase 4 49
First in 2008; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 168 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 85 across the 136 interventional studies. Of the 70 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 136 have an industry lead sponsor. The 10 most frequent:
Baudax Bio is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Baudax Bio has 9 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
15 of the studies testing dexmedetomidine in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878156Phase 3Children's Cancer Hospital Egypt 57357Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | 2026-12-30 |
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07846722Vasiliki SamartziEsmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery | 2026-12-01 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the analgesic efficacy, on Post-Operative Day (POD) 1, of DEX-IN compared with placebo, using the summed pain intensity difference over the first 48 hours (SPID48) in subjects with acute moderate to severe pain following unilateral bunionectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subject are eligible only if all the following apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Drug: Intranasal Dexmedetomidine
IN Placebo every 6 hours for 48 hours.
Drug: Intranasal Placebo
Also known as: DEX-IN
Summed Pain Intensity Difference Over the First 48 Hours (SPID48).
Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.
Time frame: 48 hours
SPID at Various Other Time Points
Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.
Time frame: Up to 48 Hours
Time to Perceptible and Meaningful Pain Relief
Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.
Time frame: 6 hours
Number of Subjects With Significant Pain Improvement Following the First Study Dose.
Time frame: 6 hours
Use of Rescue Medication (Oral Opioids)
Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose
Time frame: 48 hours
Time to First Rescue Medication Use
Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.
Time frame: 48 hours
Number of Subjects With Complete Protection From PONV
Time frame: 24 hours
| Milestone | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Started | 84 | 84 |
| Completed | 80 | 81 |
| Not completed | 4 | 3 |
| Withdrew: Lack of efficacy | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 |
Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.
| units on a scale | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Summed Pain Intensity Difference Over the First 48 Hours (SPID48). | -2328.2 ± 5746.724 | -548.90 ± 5819.373 |
Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.
| units on a scale | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| SPID 0-6 | -346.57 ± 579.0378 | -120.46 ± 590.7313 |
| SPID 0-12 | -568.89 ± 1213.410 | -151.93 ± 1263.656 |
| SPID 0-24 | -1043.2 ± 2553.890 | -239.07 ± 2717.394 |
Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.
| minutes | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Time to perceptible pain relief | 18.39 (15.50 to 25.68) | 33.0 (18.18 to 85.33) |
| Time to meaningful pain relief | 79.32 (55.25 to 151.88) | NA (NA to NA) |
| participants | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| ≥30% reduction in pain | 26 | 15 |
| ≥50% reduction in pain | 9 | 2 |
Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose
| participants | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Use of Rescue Medication (Oral Opioids) | 66 | 76 |
Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.
| hours | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Time to First Rescue Medication Use | 4.94 (4.03 to 7.85) | 2.68 (1.42 to 3.47) |
| participants | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Number of Subjects With Complete Protection From PONV | 72 | 70 |
Collected over All AEs were collected through the Day 7 study visit. All SAEs were assessed through the Day 7 visit, but were reported through 30 days of the last study visit if the investigator was made aware of the event.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DEX-IN 50mcg | — | 1/84 (1.2%) | 51/84 (60.7%) |
| IN Placebo | — | 0/84 (0%) | 36/84 (42.9%) |
| Event | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| HypotensionVascular disorders | 1/84 | 0/84 |
| Event | DEX-IN 50mcg | IN Placebo |
|---|---|---|
| Blood Pressure DecreasedInvestigations | 22/84 | 3/84 |
| NauseaGastrointestinal disorders | 13/84 | 14/84 |
| Nasal DiscomfortRespiratory, thoracic and mediastinal disorders | 7/84 | 2/84 |
| VomitingGastrointestinal disorders | 4/84 | 6/84 |
| HeadacheNervous system disorders | 6/84 | 4/84 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 4/84 | 1/84 |
| Nasal DrynessRespiratory, thoracic and mediastinal disorders | 4/84 | 3/84 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/84 | 4/84 |
| BradycardiaCardiac disorders | 3/84 | 0/84 |
| DizzinessNervous system disorders | 3/84 | 1/84 |
Safety analysis set - All subjects receiving at least one study dose
| Age, Categorical(Participants) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 82 | 81 | 163 |
| >=65 years | 2 | 3 | 5 |
| Age, Continuous(years) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| Mean | 43.9 ± 12.37 | 44.0 ± 13.08 | 44.0 ± 12.69 |
| Sex: Female, Male(Participants) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| Female | 79 | 75 | 154 |
| Male | 5 | 9 | 14 |
| Ethnicity (NIH/OMB)(Participants) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 39 | 72 |
| Not Hispanic or Latino | 51 | 45 | 96 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 21 | 41 |
| White | 59 | 56 | 115 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| United States | 84 | 84 | 168 |
| Body Mass Index (BMI)(kg/m^2) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| Mean | 26.6 ± 4.31 | 27.4 ± 4.08 | 27.0 ± 4.20 |
| Baseline pain intensity score (NPRS)(units on a scale) | DEX-IN 50mcg | IN Placebo | Total |
|---|---|---|---|
| Mean | 6.4 ± 1.42 | 6.7 ± 1.90 | 6.5 ± 1.68 |
The record gives a start of Oct 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Baudax Bio